CAR-T vs bispecific antibodies: how the choice is actually framed

What each one is, in one paragraph each

CAR-T takes your own T cells, re-engineers them in a lab to recognize your cancer, and gives them back as a single infusion after short chemotherapy (lymphodepletion). Manufacturing takes weeks. When it works, the cells persist and can hold the disease down with no ongoing drug — a treatment-free interval.

Bispecific antibodies are off-the-shelf infusions or injections that physically link your existing T cells to the cancer cell (for example, BCMA×CD3 in myeloma, CD20×CD3 in lymphoma). No manufacturing wait — dosing can start within days, continues on a schedule for months or until progression, and begins with “step-up” doses to manage early reactions.

The documented trade-offs

Speed. Bispecifics win when the disease cannot wait for cell manufacturing. This is the single most common clinical reason to start with an antibody.

Depth and durability. CAR-T’s appeal is one treatment, then freedom from maintenance. In myeloma’s pivotal studies, cilta-cel (CARTITUDE-1) showed a 97% response rate; teclistamab (MajesTEC-1) showed 63% with a median response duration of 18.4 months on continuous dosing. These trials enrolled different patients at different disease stages — comparing the percentages directly is a category error, and no completed randomized head-to-head trial exists as of this verification.

Toxicity shape. Both cause cytokine release syndrome; bispecifics more often produce lower-grade CRS managed with step-up dosing, while CAR-T concentrates risk in one high-acuity window after infusion. Continuous bispecific dosing carries an ongoing infection risk that one-time CAR-T mostly front-loads.

Logistics. CAR-T needs roughly four weeks near a cell-therapy center, then distance is fine. Bispecifics need recurring visits for as long as treatment continues — a real factor if the nearest center is a flight away.

Sequencing. Evidence on whether prior bispecific exposure dulls a later CAR-T response (or vice versa) is still developing. If both classes are realistic options for you, the order matters and is an active research question — ask, don’t assume.

Geography cuts across the choice

Access is not symmetric. Bispecifics are broadly available in the US, EU, UK, and Australia. China’s commercial strength is CAR-T — six NMPA-approved products — while bispecific availability there is narrower and changing; verify the current status of any specific antibody directly with the treating hospital. For patients who look to China for CAR-T, the usual frame is “bispecific first at home vs CAR-T now in China,” and the trade-offs above are the substance of that conversation.

Questions to ask your clinician

• Given how fast my disease is moving, can I safely wait for CAR-T manufacturing?
• For my diagnosis and prior treatments, what response duration does the evidence show for each option?
• What are the infection-prevention and monitoring requirements for each — and can I actually meet them where I live?
• If I start with a bispecific, does anything close off a later CAR-T? And the reverse?
• Which option do you have the most experience with for my exact situation?

This page explains a decision frame; it cannot make the decision. Eligibility and sequencing are clinical judgments for your treating team — our safety evidence review and CAR-T guide cover the adjacent questions.